UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________________to_____________________________________________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact nam ...

1 This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company's plans, progress, and timing relating to the Company's solid tumor programs and the presentation of data, the Company's current and future research and development plans or expectations, the structure, timing and success of the Company's planned preclinical develop ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________________to_____________________________________________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact name of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________________to_____________________________________________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 82-5282075 (State or other jurisdiction of incorporation or organization) 830 Winter Street, Walt ...

• Endpoints TScan Therapeutics, Inc. 30 1 2 3 Archival sample <6mo OR fresh biopsy Targets TSC-200 TSC-203 TSC-202 TSC-204 A*02:01A*01:01A*03:01B*07:02C*07:02 TSC-201 A*24:02 TSC-205 HPV16 Target-202 Target-201 PRAME MAGE-A1 Target-205 10+ TCRs in the clinic by the end of 2024 the early stages of building the ImmunoBank 1 2 3 4 5 6 7 8 9 0 20 40 60 80 100 Eligible patients (%) Melanoma -single NSCLC-single TScan Therapeutics, Inc. 33 TCR-T uniquely addresses myeloid leukemias Not addressable by CAR-T therap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________________to_____________________________________________________ Commission File Number 001-40603 TSCAN THERAPEUTICS, INC. (Exact name of Regist ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Del ...

Unleash Immunity Corporate Presentation September 2022 1 Disclaimers and forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding possible or assumed future results of operations of TScan Therapeutics, Inc. (the "Company", "we", "our" and "us"), expenses and financing needs, business strategies and plans, research and developmen ...

Unleash Immunity Corporate Presentation September 2022 1 Disclaimers and forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding possible or assumed future results of operations of TScan Therapeutics, Inc. (the "Company", "we", "our" and "us"), expenses and financing needs, business strategies and plans, research and developmen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...